PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Abstract

Human stem cell leukemia-lymphoma syndrome usually presents itself as a myeloproliferative disorder (MPD) that evolves to acute myeloid leukemia and/or lymphoma. The syndrome associated with t(8;13)(p11;q12) results in expression of the ZNF198-fibroblast growth factor receptor (FGFR) 1 fusion tyrosine kinase. Current empirically derived cytotoxic chemotherapy is inadequate for treatment of this disease. We hypothesized that small-molecule inhibitors of the ZNF198-FGFR1 fusion would have therapeutic efficacy. We characterized the transforming activity of ZNF198-FGFR1 in hematopoietic cells in vitro and in vivo. Expression of ZNF198-FGFR1 in primary murine hematopoietic cells caused a myeloproliferative syndrome in mice that recapitulated the human MPD phenotype. Transformation in these assays, and activation of the downstream effector molecules PLC-gamma, STAT5, and phosphatidylinositol 3-kinase/AKT, required the proline-rich domains, but not the ZNF domains, of ZNF198. A small-molecule tyrosine kinase inhibitor, PKC412 (N-benzoyl-staurosporine) effectively inhibited ZNF198-FGFR1 tyrosine kinase activity and activation of downstream effector pathways, and inhibited proliferation of ZNF198-FGFR1 transformed Ba/F3 cells. Furthermore, treatment with PKC412 resulted in statistically significant prolongation of survival in the murine model of ZNF198-FGFR1-induced MPD. Based in part on these data, PKC412 was administered to a patient with t(8;13)(p11;q12) and was efficacious in treatment of progressive myeloproliferative disorder with organomegaly. Therefore, PKC412 may be a useful therapy for treatment of human stem cell leukemia-lymphoma syndrome.

7 Figures and Tables

050100'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

425 Citations

Semantic Scholar estimates that this publication has 425 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Chen2004PKC412IT, title={PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.}, author={Jing Chen and Daniel J. Deangelo and Jeffery L. Kutok and Ifor R Williams and Benjamin Hoyoung Lee and Martha Wadleigh and Nicole Duclos and Sarah Cohen and Jennifer Adelsperger and Rachel O. Okabe and Allison Coburn and Ilene A. Galinsky and Brian J P Huntly and Pamela Schwartz Cohen and Thomas Meyer and Doriano Fabbro and Johannes L. Roesel and Lolita Banerji and James D Griffin and Sheng Xiao and Jonathan Alfred Fletcher and Richard M Stone and Dwight Gary Gilliland}, journal={Proceedings of the National Academy of Sciences of the United States of America}, year={2004}, volume={101 40}, pages={14479-84} }